With FDA Concerns Public, What's Next for These Cholesterol Drugs?

The FDA wants Regeneron (REGN), Amgen (AMGN) and Pfizer (PFE) to more closely look at their promising cholesterol fighting drugs. That could mean delays, but may not be a deathknell.

Mar 13, 2014 at 2:00PM

Investors in Regeneron (NASDAQ:REGN) Amgen (NASDAQ:AMGN), and Pfizer (NYSE:PFE) got bad news last week when the FDA reportedly contacted the companies to express concerns that their high profile PCSK9 targeting cholesterol drugs may cause adverse neurological events.

The FDA and the companies didn't provide investors with insight into what adverse events the FDA has noticed, nor did they indicate if the events were specific to one PCSK9 drug or another. That leaves investors with questions surrounding the compounds, which were previously thought to be potential blockbusters.

The news sent Regeneron's shares sharply lower; however, prices have bounced back as investors digested the report and considered that such neurological events may not mean an end for these cholesterol busting compounds.

REGN Chart

REGN data by YCharts

Targeting PCSK9 gene
It's been known for a while that patients possessing a mutation to the PCSK9 gene causing it to over-produce a protein responsible for moderating cholesterol are associated with high bad cholesterol levels.

Specifically, the protein produced by PCSK9 controls the number of LDL receptors on cells that are responsible for removing LDL from the bloodstream. That means if PCSK9 expression is limited, more receptors are present, and LDL levels drop.

That knowledge has prompted a wave of research into creating drugs that will mimic the mutation for under-expression. Regeneron, its partner Sanofi (NYSE:SNY), and Amgen have been among the leaders advancing such research, but Pfizer isn't far behind.

Why there has been so much excitement over PCSK9
Statins have been used for years to lower cholesterol, but statins don't work for everyone. Additionally, it's been shown that statins increase PCSK9 expression, which reduces statin effectiveness. That suggests that PCSK9 drugs, used alongside statins, could enhance statin efficacy.

Statins came onto the scene in the 1990's. They help control production of cholesterol in the liver, an organ responsible for up to 70% of the body's cholesterol production. The group of drugs became widely prescribed by doctors seeking to reduce arterial blockages, lowering the chance of stroke or heart attack.

On average, drugs in the statins class lowered LDL cholesterol by 1.8 mmol/l in trials, translating into a 60% reduction in the risk of heart disease and an estimated 17% reduced risk of stroke.

As a result of their widespread use, statins became some of the industry's best sellers, creating a market worth $20 billion in 2005. Pfizer's Lipitor was the best selling drug in the group for years, generating $125 billion in sales for the company between 1997 and 2011.

The ability to improve statin efficacy and the blockbuster potential from treating cardiovascular disease suggests the use of PCSK9 inhibiting drugs could be similarly high.

A higher hurdle
The FDA's splash of cold water defuses some of the excitement surrounding PCSK9, but it doesn't necessarily mean an end to PCSK9 hopefuls.

Regeneron, Sanofi, Amgen, and Pfizer hope that's the case because they've bet big that their drugs can win FDA approval.

Regeneron and Sanofi are studying their drug alirocumab in a series of 12 trials. Amgen, which has stated it still plans to file its AMG-145 PCSK9 drug with the FDA for approval this year, has 13 studies ongoing. And Pfizer's plans for RN316 include studying it in 22,000 patients.

Fool-worthy final thoughts
No one is discussing publicly the specific details surrounding the neurocognitive events outlined by the FDA. However, in a filing disclosing the FDA's concerns, Sanofi reported it's unaware of any such neurocognitive events in its trials. But that doesn't necessarily mean it's in the clear, after all the study wasn't designed to look for such events. Neither were the studies by Amgen and Pfizer.

That has the FDA asking all the companies to start digging into their data, suggesting that such digging may unearth those events later. The FDA could also create additional barriers to the drugs, including asking for additional trials specifically looking at neurocognitive events, or if approved, a more restrictive label than otherwise hoped. However, that doesn't mean investors need to panic, yet. After all, the FDA has found that the use of statins can cause neurological events including memory loss, forgetfulness, and confusion. We don't know if the PCSK9 events are similar to statins, though, which means investors should stay tuned.

This 1 stock may have fewer question marks
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers